Single Cell Technology, ABB to develop new therapeutic antibodies Pharmaceutical Business Review Under the deal, SCT will use its patented platform to screen plasma cells, measure the kinetics of secreted antibodies and sequence the cognate light and heavy chain mRNA powered by Next Generation Sequencing (NGS). The deal will see ABB select ... |
